Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27,196,692
-
Total 13F shares
-
20,382,905
-
Share change
-
-532,680
-
Total reported value
-
$105,175,826
-
Put/Call ratio
-
15%
-
Price per share
-
$5.16
-
Number of holders
-
70
-
Value change
-
-$2,839,834
-
Number of buys
-
30
-
Number of sells
-
27
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q2 2024
As of 30 Jun 2024,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,382,905 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, Artal Group S.A., ADAGE CAPITAL PARTNERS GP, L.L.C., Samsara BioCapital, LLC, Avidity Partners Management LP, Point72 Asset Management, L.P., Flagship Pioneering Inc., VANGUARD GROUP INC, Opaleye Management Inc., and Deep Track Capital, LP.
This page lists
70
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.